Ocular Allergy: Clinical, Therapeutic and Drug Discovery Considerations

Ocular Therapeutics

Volumn , Issue , 2008, Pages 239-274

  Yanni, John M ^a   Barney, Neal P ^b  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551641543     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370585-3.50013-3     Document Type: Chapter

References (246)

1. Abelson M.B., Baird R.S., Allansmith M.R. Tear histamine levels in vernal conjunctivitis and other ocular inflammations. Ophthalmology 1980, 87:812-814.
2. Abelson M.B., Butrus S.I., Weston J.H. Aspirin therapy in vernal conjunctivitis. Am. J. Ophthalmol. 1983, 95:502-505.
3. Akman A., Irkec M., Orhan M. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye 1998, 12(Pt 2):291-295.
4. Akova Y.A., Jabbur N.S., Neumann R., Foster C.S. A typical ocular atopy. Ophthalmology 1993, 100:1367-1371.
5. Akpek E.K., Dart J.K., Watson S., Christen W., Dursun D., Yoo S., O'Brien T.P., Schein O.D., Gottsch J.D. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004, 111:476-482.
6. Akpek E.K., Hasiripi H., Christen W.G., Kalayci D. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000, 107:263-269.
7. Alexander M. Comparative therapeutic studies with Tilavist. Allergy. Allergy 1995, 50:34-38. discussion.
8. Allansmith M.R. Pathology and treatment of giant papillary conjunctivitis. I. The U.S. perspective. Clin. Ther. 1987, 9:443-450.
9. Allansmith M.R., Baird R.S., Greiner J.V. Vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis compared and contrasted. Am. J. Ophthalmol. 1979, 87:544-555.
10. Allansmith M.R., Baird R.S., Greiner J.V. Density of goblet cells in vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis. Arch. Ophthalmol. 1981, 99:884-885.
11. Allansmith M.R., Korb D.R., Greiner J.V., Henriquez A.S., Simon M.A., Finnemore V.M. Giant papillary conjunctivitis in contact lens wearers. Am. J. Ophthalmol. 1977, 83:697-708.
12. Allison A.C., Almquist S.J., Muller C.D., Eugui E.M. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc. 1991, 23(Suppl. 2):10-14.
13. Anwar M.S. The role of aspirin in vernal keratoconjunctivitis. J. Coll. Physicians Surg. Pak. 2003, 13:178-179.
14. Arlt F. Physiologisch und pathologisch anatomische Bemerkungen uber die bindehaut des Auges. Prager Vierteljahrschrift 1846, 4:73.
15. Asbell P., Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Clao J. 1997, 23:31-36.
16. Aswad M.I., Tauber J., Baum J. Plasmapheresis treatment in patients with severe atopic keratoconjunctivitis. Ophthalmology 1988, 95:444-447.
17. Autrata R., Rehurek J., Holousova M. Phototherapeutic keratectomy in the treatment of corneal surface disorders in children. Cesk. Slov. Oftalmol. 2002, 58:105-111.
18. Avunduk A.M., Avunduk M.C., Dayanir V., Tekelioglu Y., Dayioglu Y.S. Pharmacological mechanism of topical lodoxamide treatment in vernal keratoconjunctivitis: a flow-cytometric study. Ophthalmic Res. 1998, 30:37-43.
19. Avunduk A.M., Avunduk M.C., Tekelioglu Y. Analysis of tears in patients with atopic keratoconjunctivitis, using flow cytometry. Ophthalmic Res. 1998, 30:44-48.
20. Avunduk A.M., Avunduk M.C., Dayioglu Y.S., Centinkaya K. Flow cytometry tear analysis in patients with chronic allergic conjunctivitis. Jpn J. Ophthalmol. 1997, 41:67-70.
21. Avunduk A.M., Avunduk M.C., Erdol H., Kapicioglu Z., Akyol N. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica 2001, 215:290-293.
22. Avunduk A.M., Avunduk M.C., Kapicioglu Z., Akyol N., Tavli L. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology 2000, 107:1333-1337.
23. Axenfeld T. Rapport sur le catarrhe printanier. Bull. Mem. Soc. Fr. Ophthalmol. 1907, 24:1.
24. Azevedo M., Castel-Branco M.G., Oliveira J.F., Ramos E., Delgado L., Almeida J. Double blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin. Exp. Allergy 1991, 21:689-694.
25. Baddeley S.M., Bacon A.S., McGill J.I., Lightman S.L., Holgate S.T., Roche W.R. Mast cell distribution and neutral protease expression in acute and chronic allergic conjunctivitis. Clin. Exp. Allergy 1995, 25:41-50.
26. Bagnasco M., Pesce G., Fiorino N., Riccio A.M., Ciprandi G., Buscaglia S., Canonica G.W. In situ hybridization analysis of ICAM-1 (CD54) mRNA on conjunctival epithelium during allergic inflammation. Clin. Exp. Allergy 1997, 27:737-743.
27. Ballow M., Mendelson L. Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis. J. Allergy Clin. Immunol. 1980, 66:112-118.
28. Bartlett J.D., Howes J.F., Ghormley N.R., Amos J.F., Laibovitz R., Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr. Eye Res. 1993, 12:313-321.
29. Begley C.G., Riggle A., Tuel J.A. Association of giant papillary conjunctivitis with seasonal allergies. Optom. Vis. Sci. 1990, 67:192-195.
30. Beigelman M.N. Vernal Conjunctivitis 1950, University of Southern California Press, Los Angeles.
31. Benelli U., Lepri A., Del Tacca M., Nardi M. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J. Ocul. Pharmacol. Ther. 1996, 12:425-431.
32. BenEzra D., Matamoros N., Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eye drops. Transplant. Proc. 1988, 20:644-649.
33. BenEzra D., Pe'er J., Brodsky M., Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am. J. Ophthalmol. 1986, 101:278-282.
34. Benhamou M., Ryba N.J., Kihara H., Nishikata H., Sirganian R.P. Protein-tyrosine kinase p72 Syk in high affinity IgE receptor signaling: identification as a component of pp72 and association with the receptor gamma-chain after receptor aggregation. J. Biol. Chem. 1993, 268:23318-23324.
35. Bertelmann E., Pleyer U. Immunomodulatory therapy in ophthalmology - is there a place for topical application?. Ophthalmologica 2004, 218:359-367.
36. Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J. Allergy Clin. Immunol. 2000, 106:1019-1032.
37. Bonini S., Pierdomenico R. Levocabastine eye drops in vernal conjunctivitis. Eur. J. Ophthalmol. 1995, 5:283-284.
38. Bonini S., Barney N.P., Schiavone M., Centofanti M., Berruto A., Allansmith M.R. Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis. Eye 1992, 6(Pt 6):648-652.
39. Bonini S., Coassin M., Aronni S., Lambiase A. Vernal keratoconjunctivitis. Eye 2004, 18:345-351.
40. Bonini S., Lambiase A., Levi-Schaffer F., Aloe L. Nerve growth factor: an important molecule in allergic inflammation and tissue remodeling. Int. Arch. Allergy Immunol. 1999, 118:159-162.
41. Bonini S., Lambiase A., Marchi S., Pasqualetti P., Zuccaro O., Rama P., Magrini L., Juhas T., Bucci M.G. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up. Ophthalmology 2000, 107:1157-1163.
42. Brockman H.L., Momsen M.M., Knudtson J.R., Miller S.T., Graff G., Yanni J.M. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 2003, 11:247-268.
43. Bruijnzeel P.L.B., Warringa R.A.J., Kok P.T.M., Kreukniet J. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br. J. Pharmacol. 1990, 99:798-802.
44. Buckley R.J. Vernal keratoconjunctivitis. Int. Ophthalmol. Clin. 1988, 28:303-308.
45. Butrus S.I., Leung D.Y., Gellis S., Baum J., Kenyon K.R., Abelson M.B. Vernal conjunctivitis in the hyperimmunoglobulinemia E syndrome. Ophthalmology 1984, 91:1213-1216.
46. Butrus S.I., Ochsner K.I., Abelson M.B., Schwartz L.B. The level of tryptase in human tears. An indicator of activation of conjunctival mast cells. Ophthalmology 1990, 97:1678-1683.
47. Calder V.L., Jolly G., Hingorani M., Adamson P., Leonardi A., Secchi A.G., Buckley R.J., Lightman S. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin. Exp. Allergy 1999, 29:1214-1222.
48. Cameron J.A. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology 1995, 102:985-993.
49. Capron M., Loiseau S., Papin J.P., Robertson S., Capron A. Inhibitory effects of lodoxamide on eosinophil activation. Int. Arch. Allergy Immunol. 1998, 116:140-146.
50. Centofanti M., Schiavone M., Lambiase A., Taffara M., Giuffrida S., Bonini S. Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. Eye 1996, 10(Pt 4):422-424.
51. Cetkovic-Cvrlje M., Dragt A.L., Vassilev A., Liu X.P., Uckun F.M. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin. Immunol. 2003, 106:213-225.
52. Cetkovic-Cvrlje M., Tibbles H.E. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Curr. Pharmaceutical Design 2004, 10:1767-1784.
53. Chang S.W., Chang C.J. Delayed tear clearance in contact lens associated papillary conjunctivitis. Curr. Eye Res. 2001, 22:253-257.
54. Chapman I., Mazzoni L. Mechanisms of inhibition by cyclosporin A on pulmonary leukocyte accumulation. TiPS 1994, 15:99-101.
55. Chaudhary K.P. Evaluation of combined systemic aspirin and cromolyn sodium in intractable vernal catarrh. Ann. Ophthalmol. 1990, 22:314-318.
56. Cirillo R., Triggiani M., Siri L., Ciccarelli A., Petit G.R., Condorelli M., Marone G. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J. Immunol. 1990, 144:3891-3897.
57. Cocoa A.F., Cooke R.A. On the classification of the phenomena of hypersensitiveness. J. Immunol. 1923, 8:163-182.
58. Cook E.B., Stahl J.L., Barney N.P., Graziano F.M. Olopatadine inhibits TNFa release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. 2000, 84:504-508.
59. Cook E.B., Stahl J.L., Barney N.P., Graziano F.M. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. 2001, 87:424-429.
60. Cook E.B., Stahl J.L., Lowe L., Chen R., Morgan E., Wilson J., Varro R., Chan A., Graziano F.M., Barney N.P. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs non-allergics. J. Immunol. Methods 2001, 254:109-118.
61. Cook E.B., Stahl J.L., Barney N.P., Graziano F.M. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr. Drug Targets - Inflamm. Allergy 2002, 1:167-180.
62. Cook E.B., Stahl J.L., Brooks A.M., Graziano F.M., Barney N.P. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest. Ophthalmol. Vis. Sci. 2006, 47:3423-3429.
63. Coombs R.R.A., Gell P.G.H. The classification of allergic reactions underlying disease. Chap. 13. Clinical Aspects of Immunology 1962, Blackwell Scientific Publications, Oxford. R.R.A. Coombs, P.G.H. Gell (Eds.).
64. Costello P.S., Turner M., Walters A.E., Cunningham C.N., Bauer P.H., Downward J., Tybulewicz V.L. Critical role for the tyrosine kinase Syk in signaling through the high affinity IgE receptor of mast cells. Oncogene 1996, 13:2595-2605.
65. D'Angelo G., Lambiase A., Cortes M., Sgrulleta R., Pasqualetti R., Lamagna A., Bonini S. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefe's Arch. Clin. Exp. Ophthalmol. 2003, 241:192-195.
66. Daugherty B.L. Commentary: histamine H4 antagonism: a therapy for chronic allergy?. Br. J. Pharmacol. 2004, 142:5-7.
67. Dechant K.L., Goa K.L. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drug Eval. 1991, 41:202-224.
68. Denis D., Bloch-Michel E., Verin P., Sebastiani A., Tazartes M., Helleboid L., Di Giovanni A., Lecorvec M. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA. Br. J. Ophthalmol. 1998, 82:1135-1138.
69. Desmarres L.A. Hypertrophie perikeratique de la conjonctive. Traite theorie et pratique des maladies des yeus 1855, Germer Baillere, Paris.
70. Dogru M., Katakami C., Nakagawa N., Tetsumoto K., Yamamoto M. Impression cytology in atopic dermatitis. Ophthalmology 1998, 105:1478-1484.
71. Dogru M., Nakagawa N., Tetsumoto K., Katakami C., Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J. Ophthalmol. 1999, 43:53-57.
72. Donshik P.C. Giant papillary conjunctivitis. Transcripts Am. Ophthalmol. Soc. 1994, 92:687-744.
73. Donshik P.C. Contact lens chemistry and giant papillary conjunctivitis. Eye & Contact Lens 2003, 29(1S):S37-S39.
74. Donshik P.C., Ballow M., Luistro A., Samartino L. Treatment of contact lens-induced giant papillary conjunctivitis. Clao J. 1984, 10:346-350.
75. + T cells. J. Immunol. 2006, 176:7062-7070.
76. Easty D.L., Birkenshaw M., Merrett T., Merret J., Entwhisstle C., Amer B. Immunological investigations in vernal eye disease. Trans. Ophthalmol. Soc. UK 1980, 100:98-107.
77. El Hennawi M. Clinical trial with 2% sodium cromoglycate (Opticrom) in vernal keratoconjunctivitis. Br. J. Ophthalmol. 1980, 64:483-486.
78. Eperon S., Sauty A., Lanz R., Leimgruber A., Lurati F., Guex-Crosier Y. Eotaxin-1 (CCL11) upregulation in tears during seasonal allergic conjunctivitis. Graefe's Arch. Clin. Exp. Ophthalmol. 2004, 242:966-970.
79. Foster C.S., Calonge M. Atopic keratoconjunctivitis. Ophthalmology 1990, 97:992-1000.
80. Foster C.S., Duncan J. Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis. Am. J. Ophthalmol. 1980, 90:175-181.
81. Foster C.S., Rice B.A., Dutt J.E. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991, 98:1190-1196.
82. Friedlaender M.H. Diseases affecting the eye and skin. Allergy and Immunology of the Eye 1979, Harper and Row, Hagerstown. M.H. Friedlaender (Ed.).
83. Fujishima H., Fukagawa K., Satake Y., Saito I., Shimazaki J., Takano Y., Tsubota K. Combined medical and surgical treatment of severe vernal keratoconjunctivitis. Jpn J. Ophthalmol. 2000, 44:511-515.
84. Fujishima H., Takeuchi T., Shinozaki N., Saito I., Tsubota K. Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. Clin. Exp. Immunol. 1995, 102:395-398.
85. Fukagawa K., Nakajima T., Tsubota K., Shimmura S., Saito H., Hirai K. Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J. Allergy Clin. Immunol. 1999, 103:1220-1221.
86. Garrity J.A., Liesegang T.J. Ocular complications of atopic dermatitis. Can. J. Ophthalmol. 1984, 19:21-24.
87. Geba G.P., Ptak W., Askenase P.W. Cyclosporin (CSA) inhibits the late component of DTH and the late phase IgE responses without affecting early DTH or the immediate phase of IgE responses. J. Allergy Clin. Immunol. 1991, 87:333.
88. Geggel H.S. Successful penetrating keratoplasty in a patient with severe atopic keratoconjunctivitis and elevated serum IgE level treated with long-term topical cyclosporin A. Cornea 1994, 13:543-545.
89. Ghoraishi M., Akova Y.A., Tugal-Tutkun I., Foster C.S. Penetrating keratoplasty in atopic keratoconjunctivitis. Cornea 1995, 14:610-613.
90. Giuri S., Munteanu G.H. An efficacy study of lodoxamide treatment in allergic eye lesions. Oftalmologia 2000, 50:68-76.
91. Grant S.M., Goa K.L., Fitton A., Sorkin E.M. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders. Drugs 1990, 40:412-448.
92. Gunduz K., Ucakhan O., Budak K., Eryilmaz T., Ozkan M. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis. Ophthalmic Res. 1996, 28:80-87.
93. Gupta S., Khurana A.K., Ahluwalia B.K., Gupta N.C. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol. (Copenh.) 1991, 69:95-98.
94. Gupta V., Sahu P.K. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye 2001, 15:39-41.
95. Gutzmer R., Diestel C., Mommert S., Kother B., Stark H., Wittmann M., Werfel T. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J. Immunol. 2005, 174:5224-5232.
96. Hallberg C.K. Eosinophil peroxidase and eosinophil-derived neurotoxin toxicity on cultured human corneal epithelium. Invest. Ophthalmol. Vis. Sci. 1995, 36:S698.
97. Henriquez A.S., Kenyon K.R., Allansmith M.R. Mast cell ultrastructure. Comparison in contact lens-associated giant papillary conjunctivitis and vernal conjunctivitis. Arch. Ophthalmol. 1981, 99:1266-1272.
98. Herbert H. Preliminary note on the pathology and diagnosis of spring catarrh. Br. Med. J. 1903, 1903:735.
99. Hingorani M., Calder V.I., Buckley R.J., Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 1999, 40:392-399.
100. Hingorani M., Calder V., Jolly G., Buckley R.J., Lightman S.L. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J. Allergy Clin. Immunol. 1998, 102:821-830.
101. Hingorani M., Moodaley L., Calder V.I., Buckley R.J., Lightman S. A randomized, placebo controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998, 105:1715-1720.
102. Hoang-Xuan T., Prisant O., Hannouche D., Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology 1997, 104:1300-1305.
103. Hofstra C.L., Desai P.J., Thurmond R.L., Fung-Leung W.-P. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 2003, 305:1212-1221.
104. Hogan M.J. Atopic keratoconjunctivitis. Am. J. Ophthalmol. 1953, 36:937-947.
105. Holland E.J., Olsen T.W., Ketcham J.M., Florine C., Krachmer J.H., Purcell J.J., Lam S., Tessler H.H., Sugar J. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993, 12:413-419.
106. Holsclaw D.S., Whitcher J.P., Wong I.G., Margolis T.P. Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am. J. Ophthalmol. 1996, 121:243-249.
107. Hsieh K.H., Chou C.C., Huang S.F. Interleukin 2 therapy in severe atopic dermatitis. J. Clin. Immunol. 1991, 11:22-28.
108. Hurlbut W.B., Damonkos A.N. Cataract and retinal detachment associated with atopic dermatitis. Arch. Ophthalmol. 1961, 52:852-857.
109. Hutchcroft J.E., Geahlen R.L., Deanin G.G., Oliver J.M. FceRI-mediated tyrosine phosphorylation and activation of the 72 kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. Proc. Natl. Acad. Sci. USA. 1992, 89:9107-9111.
110. Irani A.M., Butrus S.I., Tabbara K.F., Schwartz L.B. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 1990, 86:34-40.
111. Irani A.A., Schechter N.M., Craig S.S., DeBlois G., Schwartz L.B. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl Acad. Sci. USA 1986, 83:4464-4468.
112. Jay J.L. Clinical features and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate. Br. J. Ophthalmol. 1981, 65:335-340.
113. Jones B.R. Vernal keratitis. Trans. Ophthalmol. Soc. UK 1961, 81:215-228.
114. Jorgensen K.A., Koefoed-Nielsen P.B., Karaperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporine A and tacrolimus. Scand. J. Immunol. 2003, 57:93-98.
115. Joseph M.A., Kaufman H.E., Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005, 24:417-420.
116. Katelaris C.H. Ocular allergy: implications for the clinical immunologist. Ann. Allergy Asthma Immunol. 2003, 90:23-27.
117. Kiani A., Rao A., Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000, 12:359-372.
118. + T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest. Ophthalmol. Vis. Sci. 2001, 42:1285-1292.
119. Kinet J.P., Jouvin M.H., Paolini R., Numerof R., Scharenberg A. IgE receptor (FceRI) and signal transduction. Eur. Respir. J. 1996, 9(Suppl. 22):116s-118s.
120. Kino T., Hatanaka H., Hashimoto H., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J. Antibiot. 1987, 40:1249-1255.
121. Klemens F. Dermatose, Kataradt und ablatioretinae. Klin. Monatsbl. Augenheilkd. 1966, 152:921-927.
122. Knapp S., Bertelmann E., Hartmann C., Keipert S., Pleyer U. Intraocular availability of topically applied mycophenolate mofetil in rabbits. J. Ocul. Pharmacol. Ther. 2003, 19:181-192.
123. Krasny J. Alomide, a preventive immunopharmaceutical agent, in the treatment of ocular atopy. Cesk. Slov. Oftalmol. 1998, 54:41-45.
124. Kulkarni P.S. Steroidal and nonsteroidal drugs in endotoxin-induced uveitis. J. Ocul. Pharmacol. Ther. 1994, 10:329-334.
125. Kurose I., Argenbright L.W., Wolf R., Lianxi L., Granger N. Ischemia/reperfusion-induced microvascular dysfunction: role of oxidants and lipid mediators. Am. J. Physiol. 1997, 272:H2976-H2982.
126. Lambiase A., Bonini S., Rasi G., Coassin M., Bruscolini A. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch. Ophthalmol. 2003, 121:615-620.
127. Lanier B.Q., Tremblay N., Smith J.P., deFaller J.M. A double masked comparison of ocular decongestants as therapy for allergic conjunctivitis. Ann. Allergy 1983, 50:174-177.
128. Larkin G., Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999, 106:370-374.
129. Lemrini F., Dafrallah L., Sebbahi F., Rafi M. Treatment of vernal conjunctivitis with aspirin. Rev. Int. Trach. Pathol. Ocul. Trop. Subtrop. Sante Publique 1989, 66:119-127.
130. Leonardi A. Emerging drugs for ocular allergy. Expert Opin. Emerging Drugs 2005, 10:505-520.
131. Leonardi A., Abatangelo G., Cortivo R., Secchi A.G. Collagen types I and III in giant papillae of vernal keratoconjunctivitis. Br. J. Ophthalmol. 1995, 79:482-485.
132. Leonardi A., Borghesan F., Averello A., Plebani M., Secchi A.G. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protien in vernal keratoconjunctivitis. Br. J. Ophthalmol. 1997, 81:23-26.
133. Leonardi A., Borghesan F., Faggian D., Depaoli M., Secchi A.G., Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am. J. Ophthalmol. 2000, 129:151-158.
134. Leonardi A., Brun P., Tavolato M., Abatangelo G., Plebani M., Secchi A.G. Growth factors and collagen distribution in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 2000, 41:4175-4181.
135. Leonardi A., DeFranchis G., Fregona I.A., Violato D., Plebani M., Secchi A.G. Effects of cyclosporin A on human conjunctival fibroblasts. Arch. Ophthalmol. 2001, 119:1512-1517.
136. Leonard W.J., O'Shea J.J. Jaks and Stats: biological implications. Annual Rev. Immunol. 1998, 16:293-322.
137. Liu C., Wilson S.J., Kuei C., Lovenberg T.W. Comparison of human, mouse, rat and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 2001, 299:121-130.
138. Luskova P., Draber P. Modulation of the Fce receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr. Pharmaceutical Design 2004, 10:1727-1737.
139. Mach R., Rozsival P., Jilek D. Steroid glaucoma in severe atopic keratoconjunctivitis. A reminder for possible therapy with plasmapheresis. Cesk. Oftalmol. 1992, 48:167-170.
140. Macleod J.D., Anderson D.F., Baddeley S.M., Holgate S.T., McGill J.I., Roche W.R. Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. Clin. Exp. Allergy 1997, 27:1328-1334.
141. Malaviya R., Chen C.L., Navara C., Malaviya R., Liu X.P., Keenan M., Waurzyniak B., Uckun F.M. Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3',5'-dibromo-4'-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther. 2000, 295:912-926.
142. Malaviya R., Zhu D., Dibirdik I., Uckun F.M. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J. Biol. Chem. 1999, 274:27028-27038.
143. Mascarell L., Truffa-Bachi P. New aspects of cyclosporine mode of action: from gene silencing to gene up-regulation. Mini Reviews Med. Chem. 2003, 3:205-214.
144. Matsukura M., Yajima A., Yamazaki F., Yudate T., Yamada H., Tezuka T. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol. Appl. Skin Physiol. 2003, 16:405-410.
145. Mayer K., Reinhard T., Reis A., Bohringer D., Sundmacher R. FK-506 ointment 0.1%: a new therapeutic option for atopic blepharitis. Clinical trials with 14 patients. Klin. Monatsbl. Augenheidkd. 2001, 218:733-736.
146. McTavish D., Sorkin E.M. Azelastine: a review of its pharmcodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989, 38:778-800.
147. Meisler D.M., Berzins U.J., Krachmer J.H., Stock E.L. Cromolyn treatment of giant papillary conjunctivitis. Arch. Ophthalmol. 1982, 100:1608-1610.
148. Mendicute J., Aranzasti C., Eder F., Ostolaza J.I., Salaberria M. Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis. Eye 1997, 11(Pt 1):75-78.
149. Meric-Bernstam F., Mills G.B. Mammalian target of rapamycin. Seminars Oncol. 2004, 31(Suppl. 16):10-17.
150. Messmer E.M., May C.A., Stefani F.H., Welge-Luessen U., Kampik A. Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am. J. Ophthalmol. 2002, 134:816-821.
151. Metz D.P., Bacon A.S., Holgate S., Lightman S.L. Phenotypic characterization of T-cells infiltrating the conjunctiva in chronic allergic eye disease. J. Allergy Clin. Immunol. 1996, 98:686-696.
152. Metz D.P., Hingorani M., Calder V.L., Buckley R.J., Lightman S.L. T-cell cytokines in chronic allergic eye disease. J. Allergy Clin. Immunol. 1997, 100:817-824.
153. Meyer E., Kraus E., Zonis S. Efficacy of antiprostaglandin therapy in vernal conjunctivitis. Br. J. Ophthalmol. 1987, 71:497-499.
154. Miyoshi T., Fukagawa K., Shimmura S., Fujishima H., Takano Y., Takamura E., Tsubota K., Saito H., Oguchi Y. Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. Cornea 2001, 20:743-747.
155. Montan P.G., van Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br. J. Ophthalmol. 1996, 80:556-560.
156. Morgan S.J., Williams J.H., Walls A.F., Church M.K., Holgate S.T., McGill J.I. Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva. J. Allergy Clin. Immunol. 1991, 87:111-116.
157. Mukhopadhyay K., Pradhan S.C., Mathur J.S., Gambhir S.S. Studies on histamine and histaminase in spring catarrh (vernal conjunctivitis). Int. Arch. Allergy Appl. Immunol. 1981, 64:464-468.
158. Munro C.S., Higgins E.M., Marks J.M., Daly B.M., Friedmann P.S., Shuster S. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br. J. Derm. 1991, 124:43-48.
159. Muromoto K., Shoji J., Inada N., Sawa M., Kato H. Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis. Nippon Ganka Gakkai Zasshi 2006, 110:13-18.
160. Nakamura Y., Sotozona C., Kinoshita S. Inflammatory cytokines in normal human tears. Curr. Eye Res. 1998, 17:673-676.
161. Nimmo Wilkie J.S., Yager J.A., Wilkie B.N., Parker W.M. Abnormal cutaneous response to mitogens and a contact allergen in dogs with atopic dermatitis. Vet. Immunol. Immunopathol. 1991, 28:97-106.
162. Nishiwaki-Dantas M.C., Dantas P.E., Pezzutti S., Finzi S. Surgical resection of giant papillae and autologous conjunctival graft in patients with severe vernal keratoconjunctivitis and giant papillae. Ophthal. Plast. Reconstr. Surg. 2000, 16:438-442.
163. Nnoruka E.N. Current epidemiology of atopic dermatitis in south-eastern Nigeria. Int. J. Dermatol. 2004, 43:739-744.
164. Noble S., McTavish D. Levocabastine: an update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drug Eval. 1995, 50:1032-1049.
165. Norris A.A. Pharmacology of sodium cromoglycate. Clin. Exp. Allergy 1996, 26:5-7.
166. Oda T., Morikawa N., Saito Y., Masuho Y., Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275:36781-37686.
167. Oguz H., Bitiren M., Aslan O.S., Ozardali I. Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis. Acta Med. Okayama 1999, 53:123-126.
168. Ohmori K., Hasegawa K., Tamura T., Miyake K., Matsubara M., Masaki S., Karasawa A., Urayama N., Horikoshi K., Kajita J., Hasegawa M., Taniguchi K., Komada T., Kawamoto Y. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneim. Forsch. 2004, 12:809-829.
169. Ohmori K., Hayashi K.-I., Kaise T., Ohshima E., Kobayashi S., Yamazaki T., Mukouyama A. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol. 2002, 88:379-397.
170. Okada K., Sakata H., Minamoto A., Fujihara M. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 1996, 210:175-179.
171. Okayama Y., Benyon R.C., Rees P.H., Lowman M.A., Hillier K., Church M.K. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, tonsil, adenoid and intestine. Clin. Exp. Allergy 1992, 22:401-409.
172. Okayama Y., Church M.K. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int. Arch. Allergy Immunol. 1992, 97:216-225.
173. Ono S.J., Abelson M.B. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. 2005, 115:118-122.
174. Ostler H.B., Martin R.G., Dawson C.R. The use of disodium cromoglycate in the treatment of atopic ocular disease. Symposium on Ocular Therapy 1977, 99-108. John Wiley, New York. J.G. Leopold, R.D. Burns (Eds.).
175. Pandey S.K., Saini J.S., Werner L., Apple D.J. Mitomycin-C and vernal conjunctivitis. Ophthalmology 2000, 107:2125-2127.
176. Papageorgiou A.C., Wikman L.E.K. Is JAK3 a new drug target for immunomodulation-based therapies?. TiPS 2004, 25:558-562.
177. Potter P.C. Update on sublingual immunotherapy. Ann. Allergy Asthma Immunol. 2006, 96:S22-S25.
178. Power W.J., Tugal-Tutkun I., Foster C.S. Longterm follow-up of patients with atopic keratoconjunctivitis. Ophthalmology 1998, 105:637-642.
179. Pucci N., Novembre E., Cianferoni A., Lombardi E., Bernardini R., Caputo R., Campa L., Vierucci A. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann. Allergy Asthma Immunol. 2002, 89:298-303.
180. Rahi A.H.S. Pathology of corneal plaque in vernal keratoconjunctivitis. Advances in Immunology and Immunopathology of the Eye 1985, Masson, New York. G.R. O'Connor, J.W. Chandler (Eds.).
181. Rao S.K., Meenakshi S., Srinivasan B., Baluswamy S. Perilimbal bulbar conjunctival pigmentation in vernal conjunctivitis: prospective evaluation of a new clinical sign in an Indian population. Cornea 2004, 23:356-359.
182. Rich L.F., Hanifin J.M. Ocular complications of atopic dermatitis and other eczemas. Int. Ophthalmol. Clin. 1985, 25:61-76.
183. Rikkers S.M., Holland G.N., Drayton G.E., Michel F.K., Torres M.F., Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am. J. Ophthalmol. 2003, 135:297-302.
184. Rimas M., Kjellman N.I., Blychert L.O., Bjorksten B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 1990, 45:18-21.
185. Roberge F.G., Xu D., Chan C.C., de Smet M.D., Nussenblatt R.B., Chen H. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr. Eye Res. 1993, 12:197-203.
186. Romagnani S. Regulation and deregulation of human IgE synthesis. Immunol. Today 1990, 11:316-321.
187. Rossenwasser L.J., O'Brien T., Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr. Med. Res. Opin. 2005, 21:1377-1387.
188. Rouher N., Pilon F., Dalens H., Fauquert J.L., Kemeny J.L., Rigal D., Chiambaretta F. Implantation of preserved human amniotic membrane for the treatment of shield ulcers and persistent corneal epithelial defects in chronic allergic keratoconjunctivitis. J. Fr. Ophthalmol. 2004, 27:1091-1097.
189. Saini J.S., Gupta A., Pandey S.K., Gupta V., Gupta P. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol. Scand. 1999, 77:515-518.
190. Sankarkumar T., Panda A., Angra S.K. Efficacy of cryotherapy in vernal catarrh. Ann. Ophthalmol. 1992, 24:253-256.
191. Sarac O., Erdener U., Irkec M., Us D., Gungen Y. Tear eotaxin levels in giant papillary conjunctivitis associated with ocular prosthesis. Ocul. Immunol. Inflamm. 2003, 11:223-230.
192. Schindler C. Cytokines and JAK-STAT signaling. Exp. Cell Res. 1999, 253:7-14.
193. Schoch C. In vitro inhibition of human conjunctival mast cell degranulation by ketotifen. J. Ocul. Pharmacol. Ther. 2003, 19:75-81.
194. Secchi A.G., Tognon M.S., Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am. J. Opthalmol. 1990, 110:641-645.
195. Sethi H.S., Wangh V.B., Rai H.K. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Indian J. Ophthalmol. Indian J. Ophthalmol. 2002, 50:161-161. discussion.
196. Sharif N.A., Hellberg M.R., Yanni J.M. Antihistamines, Topical Ocular. Berger's Medicinal Chemistry and Drug Discovery 1997, 5:255-279. John Wiley & Sons, Inc, New York. fifth ed. M.E. Wolff (Ed.).
197. Sharif N.A., Xu S.X., Magnino P.E., Pang I.-H. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic and inflammatory diseases. Exp. Eye Res. 1996, 63:169-178.
198. Sharif N.A., Xu S.X., Miller S.T., Gamache D.A., Yanni J.M. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther. 1996, 278:1252-1261.
199. Sharif N.A., Xu S.X., Yanni J.M. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 1996, 12:401-407.
200. Sharif N.A., Xu S.X., Yanni J.M. Emedastine: a potent, high affinity histamine H1-receptor selective antagonist for ocular use: receptor binding and second messenger studies. J. Ocul. Pharmacol. 1994, 10:653-664.
201. Sharif N.A., Xu S.X., Yanni J.M. Histamine receptor-subtype affinities, selectivities, and potencies of emedastine, a novel H1-selective antagonist, and other ocularly employed antihistamines. Drug Dev. Res. 1994, 33:448-453.
202. Sharma A., Gupta R., Ram J., Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J. Ophthalmol. 1997, 45:177-180.
203. Shoji J., Inada N., Sawa M. Antibody arraygenerated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J. Ophthalmol. 2006, 50:195-204.
204. Sloper C.M., Powell R.J., Dua H.S. Tacrolimus (FK-506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001, 108:1838-1844.
205. Sompolinsky D. A contribution to the immunopathology of vernal keratoconjunctivitis. Documenta Ophthalmologica 1982, 53:61-92.
206. Sorkin E.M., Ward A. Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease. Drugs 1986, 31:131-148.
207. Sridhar M.S., Sangwan V.S., Bansal A.K., Rao G.N. Amniotic membrane transplantation in the management of shield ulcers of vernal keratoconjunctivitis. Ophthalmology 2001, 108:1218-1222.
208. Srinivas C. Adjuvant therapy of aspirin and cromoglycate 2% eye drops in vernal conjunctivitis. Korean J. Ophthalmol. 1989, 3:42-46.
209. Stock E.L., Bielory L. Treatment of ocular allergy. Immunol. Allergy Clin. N. Amer. 1997, 17:75-87.
210. Sud R.N., Greval R.S., Bajwa R.S. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J. Med. Sci. 1995, 49:205-209.
211. Suzuki S., Goto E., Dogru M., Asano-Kato N., Matsumoto Y., Hara Y., Fujishima H., Tsubota K. Tear film lipid layer alterations in allergic conjunctivitis. Cornea 2006, 25:277-280.
212. Tabbara K.F., al-Kharashi S.A. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br. J. Ophthalmol. 1999, 83:180-184.
213. Tabbara K.F., Arafat N.T. Cromolyn effects on vernal keratoconjunctivitis in children. Arch. Ophthalmol. 1977, 95:2184-2186.
214. Tan M.E., Demirci G., Pearce D., Jalbert I., Sankaridurg P., Willcox M.D. Contact lensinduced papillary conjunctivitis is associated with increased albumin deposits on extended wear hydrogel lenses. Adv. Exp. Med. Biol. 2002, 506:951-955.
215. Tanaka M., Takano Y., Dogru M., Fukagawa K., Asano-Kato N., Tsubota K., Fujishima H. A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis. Cornea 2004, 23:326-329.
216. Taniguchi T., Kobayashi T., Kondo J., Takahashi K., Nakamura H., Suzuki J., Nagai K., Yamada T., Nakamura S., Yamamura H. Molecular cloning of a porcine gene Syk that encodes a 72 kda protein tyrosine kinase showing high susceptibility to proteolysis. J. Biol. Chem. 1991, 266:15790-15796.
217. Tasaka K. Epinastine: an update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs of Today 2000, 36:735-757.
218. Temprano J. Corneal epithelial expression of ICAM-1 in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 1995, 36:S1024.
219. Thoft R.A. Keratoepithelioplasty. Am. J. Ophthalmol. 1984, 97:1-6.
220. Thompson J.E. JAK protein kinase inhibitors. Drug New Perspect. 2005, 18:305-310.
221. Thurmond R.L., Desai P.J., Dunford P.J., Fung-Leung W.-P., Hofstra C.L., Jiang W., Nguyen S., Riley J.P., Sun S., Williams K.N., Edwards J.P., Karlsson L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J. Pharmacol. Exp. Ther. 2004, 309:404-413.
222. Tomida I., Schlote T., Brauning J., Heide P.E., Zierhut M. Cyclosporin A. Ophthalmol. 2002, 99:761-767.
223. Trantas A. Sur le catarrhe printanier. Arch. Ophthalmol. (Paris) 1910, 30:593-621.
224. Triggiani M., Cirillo R., Lichtenstein L., Marone G. Inhibition of histamine and prostaglandin D2 release from human lung mast cells by cyclosporin A. Int. Arch. Allergy Appl. Immunol. 1989, 88:253-255.
225. Trocme S.D., Kephart G.M., Allansmith M.R., Bourne W.M., Gleich G.J. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am. J. Ophthalmol. 1989, 108:57-63.
226. Tuft S.J., Kemeny D.M., Dart J.K., Buckley R.J. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991, 98:150-158.
227. Uchio E., Matsuura N., Kadonosono K., Ohno S., Uede T. Tear osteopontin levels in patients with allergic conjunctival diseases. Graefe's Arch. Clin. Exp. Ophthalmol. 2002, 240:924-928.
228. Uchio E., Ono S.Y., Ikezawa Z., Ohno S. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin. Exp. Allergy 2000, 30:103-109.
229. Venza I., Visalli M., Ceci G., Teti D. Quantitative determination of histamine in tears during conjunctivitis by a novel HPLC method. Ophthalmic Res. 2004, 36:62-69.
230. Verin P., Allewaert R., Joyaux J.C., Piozzi E., Koliopoulos J., Bloch-Michel E. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur. J. Ophthalmol. 2001, 11:120-125.
231. Verin P.H., Dicker I.D., Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the longterm management of vernal keratoconjunctivitis. Clin. Exp. Allergy 1999, 29:529-536.
232. Vesaluoma M., Rosenberg M.E., Teppo A., Gronhagen-Riska C., Haahtela T., Tervo T. Tumour necrosis factor alpha (TNFalpha) in tears of atopic patients after conjunctival allergen challenge. Clin. Exp. Allergy 1999, 29:537-542.
233. von Graefe A. Klinische Vortrage uber Augenheilkunde. Journal Hirshberg 1871, 21.
234. Ward S.L. The barrier properties of an in vitro human corneal epithelial model are not altered by eosinophil major basic protein or eosinophil cationic protein. Invest. Ophthalmol. Vis. Sci. 1995, 36:S699.
235. Wiederrecht G.J., Sabers C.J., Brunn G.J., Martin M.M., Dumont F.J., Abraham R.T. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res. 1995, 1:53-71.
236. Weimer L.K., Gamache D.A., Yanni J.M. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: inhibition by the histamine H1 antagonist emedastine. Int. Arch. Allergy Immunol. 1998, 115:288-293.
237. Wood T.S., Stuart R.H., Bowma R.W., McCulley J.P., Reaves T.A. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 1988, 95:822-826.
238. Yamamoto N., Takeshita K., Shichijo M., Kokubo T., Sato M., Nakashima K., Ishimori M., Nagai H., Li Y.K., Yura T., Bacon K.B. The orally available spleen tyrosine kinase inhibitor 2-[7(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin5-ylamino] nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 2003, 306:1174-1181.
239. Yanni J.M., Miller S.T., Gamache D.A., Spellman J.M., Xu S., Sharif N.A. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol. 1997, 79:541-545.
240. Yanni J.M., Sharif N.A., Gamache D.A., Miller S.T., Weimer L.K., Spellman J.M. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. ACTA Ophthalmol. Scand. 1999, 77:33-37.
241. Yanni J.M., Weimer L.K., Sharif N.A., Xu S.X., Gamache D.A., Spellman J.M. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol. 1999, 117:643-647.
242. Yanni J.M., Stephens D.J., Miller S.T., Weimer L.K., Graff G., Parnell D., Lang L.S., Spellman J.M., Brady M.T., Gamache D.A. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocul. Pharmacol. Ther. 1996, 12:389-400.
243. Yanni J.M., Stephens D.J., Parnell D.W., Spellman J.M. Preclinical efficacy of emedastine: a potent, selective histamine H1 antagonist for topical ocular use. J. Ocul. Pharmacol. 1994, 10:665-675.
244. Yoneda K., Okamoto H., Wada Y., Morita K., Takahashi M., Ogura Y., Imamura S. Atopic retinal detachment. Report of four cases and a review of the literature. Br. J. Dermatol. 1995, 133:586-591.
245. Zhan H., Smith L., Calder V., Buckley R., Lightman S. Clinical and immunological features of atopic keratoconjunctivitis. Int. Ophthalmol. Clin. 2003, 43:59-71.
246. Zhang J., Bernstein E.H., Evans R.L., Sirganian R.P. Transfection of Syk protein tyrosine kinase reconstitues high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J. Exp. Med. 1996, 184:71-79.